Crystal Adam
Known title: President, R&DCIK: 0001825445
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
Transaction History
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 10/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 26,400 | $646K | 10/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 600 | $15K | 10/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 9/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 27,000 | $604K | 9/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 8/3/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 5,267 | $141K | 8/3/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 21,733 | $594K | 8/3/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 7/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 7,371 | $223K | 7/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 19,629 | $576K | 7/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 6/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 6,140 | $137K | 6/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 20,860 | $481K | 6/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 5/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 25,900 | $549K | 5/1/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 1,100 | $24K | 5/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 38,460 | $200K | 4/15/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 38,460 | $962K | 4/15/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 27,000 | $572K | 4/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 27,000 | $140K | 4/1/2026 | View on chart |
| TNGX | ▲ Buy | Option Exercise | 12,000 | $62K | 3/25/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 12,000 | $241K | 3/25/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 20,251 | $304K | 3/5/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 54,345 | $694K | 2/25/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 18,251 | $224K | 2/3/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 201 | $3K | 2/3/2026 | View on chart |
| TNGX | ▲ Buy | Grant | 47,460 | $0 | 2/2/2026 | View on chart |
| TNGX | ▼ Sell | Open Market | 6,851 | $22K | 2/5/2025 | View on chart |
| TNGX | ▼ Sell | Open Market | 7,432 | $22K | 2/4/2025 | View on chart |
| TNGX | ▲ Buy | Grant | 53,015 | $0 | 2/3/2025 | View on chart |
| TNGX | ▼ Sell | Open Market | 4,083 | $52K | 2/7/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 4,288 | $54K | 2/6/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 46,599 | $0 | 2/1/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 7,507 | $63K | 11/1/2023 | View on chart |
| TNGX | ▲ Buy | Grant | 81,250 | $0 | 3/1/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 | View on chart |
| CCCC | ▼ Sell | Open Market | 13,946 | $441K | 1/4/2022 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,054 | $34K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 15,000 | $97K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 5,000 | $32K | 12/22/2021 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 10,000 | $65K | 10/8/2021 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 15,000 | $75K | 10/1/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 1,712 | $76K | 10/1/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 5,112 | $235K | 10/1/2021 | View on chart |
| CCCC | ▼ Sell | Open Market | 8,176 | $371K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.